Rescue inhalers are hand-held medical devices used to deliver reliever medications for acute relief from symptoms of asthma attack or exacerbation. They contain short acting bronchodilators which help open constricted airways and provide instant relief to patients suffering from shortness of breath, wheezing, coughing, and chest tightness due to asthma. With rising prevalence of asthma globally and growing risk of severe asthma attacks, the demand for rescue inhalers has increased significantly over the years.
The global rescue inhaler market is estimated to be valued at US$ 15.5 Bn in 2023 and is expected to exhibit a CAGR of 8.8% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights.
Opportunity: Addressing Severe Asthma Attacks
One of the key opportunities in rescue inhaler market is to address increasing incidence of severe asthma attacks across the globe. Severe asthma attacks may turn life-threatening if not treated on priority. According to the Global Burden of Disease Study (GBD), around 650,000 people worldwide die due to asthma annually. During an asthma attack, the muscles around the airways tighten, swell and produce extra mucus, blocking airflow to lungs. Rescue inhalers have proved highly effective in opening constricted airways and providing immediate relief from asthma exacerbations. Thus, innovating more effective rescue inhaler formulations to combat severe asthma attacks will fuel the market growth over the forecast period.
Porter's Analysis
Threat of new entrants: Low as the rescue inhaler market requires substantial R&D investments and regulations. Existing players have established brand names.
Bargaining power of buyers: Moderate as buyers have a few substitute products to choose from. However, buyers prefer well-known brands for critical products like rescue inhalers.
Bargaining power of suppliers: Moderate as suppliers of raw materials and components have differing capacities. Suppliers play a vital role in manufacturing rescue inhalers.
Threat of new substitutes: Low as rescue inhalers are essential medications with few substitutes for emergency relief from asthma attacks.
Competitive rivalry: High among major global players due to their widespread geographic presence and wide product portfolios. Companies focus on product innovation and promotional strategies.
SWOT Analysis
Strengths: Well established brands, wide product ranges catering to varying severities, extensive R&D capabilities.
Weaknesses: Heavy reliance on generics, pricing pressures from regulators, supply chain disruptions.
Opportunities: Untapped growth potential in developing nations, rising environmental pollution and lifestyle changes augmenting asthma prevalence, scope for connected devices.
Threats: Stringent regulations, healthcare reforms cutting reimbursements, patent expiries opening door for biosimilars.
Key Takeaways
The global rescue inhaler market is expected to witness high growth over the forecast period supported by a growing asthma patient pool globally. The global rescue inhaler market is estimated to be valued at US$ 15.5 Bn in 2023 and is expected to exhibit a CAGR of 8.8% over the forecast period 2023-2030.
North America dominates currently due to reactive healthcare spending and asthma awareness campaigns. However, Asia Pacific is likely to surge due to expanding medical insurance, pollution control mandates and lifestyle changes.
Key players in the regional analysis are GSK plc, Teva Pharmaceutical Industries Ltd., and Cipla Inc. Regional analysis fastest growing and dominating region is Asia Pacific due to rising incomes, awareness, and healthcare reforms in China, India and other developing countries.
Key players operating in the rescue inhaler market are GSK plc., Teva Pharmaceutical Industries Ltd., Cipla Inc., PARI Pharma GmbH, Lupin, AstraZeneca, Boehringer Ingelheim International GmbH., Novartis, Pfizer, Sunovion Pharmaceuticals, 3M, OMRON Healthcare Co., Ltd., Koninklijke Philips N.V., Schiller, and Teleflex Incorporated.
